625 related articles for article (PubMed ID: 17052420)
1. Febrile neutropenia in paediatric peripheral blood stem cell transplantation, in -vitro sensitivity data and clinical response to empirical antibiotic therapy.
Ansari SH; Nasim S; Ahmed A; Irfan M; Ishaque A; Farzana T; Panjwani VK; Taj M; Shamsi TS
J Coll Physicians Surg Pak; 2006 Nov; 16(11):704-8. PubMed ID: 17052420
[TBL] [Abstract][Full Text] [Related]
2. [Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia. Analysis of the primary response and of a global sequential strategy in 126 episodes].
Figuera A; Tomás JF; Hernández L; Jiménez ML; Peñarrubia MJ; del Rey MC; Arranz R; Cámara R; López-Lorenzo JL; Fernández-Rañada JM
Rev Clin Esp; 1996 Aug; 196(8):515-22. PubMed ID: 8984537
[TBL] [Abstract][Full Text] [Related]
3. Meropenem plus amikacin versus piperacillin-tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children.
Aksoylar S; Cetingül N; Kantar M; Karapinar D; Kavakli K; Kansoy S
Pediatr Hematol Oncol; 2004 Mar; 21(2):115-23. PubMed ID: 15160510
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusion of ceftazidime for patients with breast cancer and multiple myeloma receiving high-dose chemotherapy and peripheral blood stem cell transplantation.
Egerer G; Goldschmidt H; Hensel M; Harter C; Schneeweiss A; Ehrhard I; Bastert G; Ho AD
Bone Marrow Transplant; 2002 Oct; 30(7):427-31. PubMed ID: 12368954
[TBL] [Abstract][Full Text] [Related]
5. Cefepime plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Lim YS; Zulkifli SZ; Zarina AL; Nordiah AJ; Jamal R
Singapore Med J; 2007 Jul; 48(7):615-9. PubMed ID: 17609821
[TBL] [Abstract][Full Text] [Related]
6. Treatment of febrile episodes in neutropenic leukemic patients with the antibiotic combinations piperacillin or ceftazidime plus amikacin: results of a randomized study.
Fenu S; Raccah R; Santilli S; Micozzi A; Girmena C; Martino P; Avvisati G
Chemioterapia; 1988 Oct; 7(5):323-6. PubMed ID: 3066517
[TBL] [Abstract][Full Text] [Related]
7. Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime.
Raad II; Escalante C; Hachem RY; Hanna HA; Husni R; Afif C; Boktour MR; Whimbey EE; Kontoyiannis D; Jacobson K; Kantarjian H; Levett LM; Rolston KV
Cancer; 2003 Sep; 98(5):1039-47. PubMed ID: 12942573
[TBL] [Abstract][Full Text] [Related]
8. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: a prospective randomized trial.
Harter C; Schulze B; Goldschmidt H; Benner A; Geiss HK; Hoppe-Tichy T; Ho AD; Egerer G
Bone Marrow Transplant; 2006 Feb; 37(4):373-9. PubMed ID: 16400334
[TBL] [Abstract][Full Text] [Related]
9. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies.
Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M
Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671
[TBL] [Abstract][Full Text] [Related]
10. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
[TBL] [Abstract][Full Text] [Related]
11. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
[TBL] [Abstract][Full Text] [Related]
12. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenic patients: a prospective randomized pilot study.
Böhme A; Shah PM; Stille W; Hoelzer D
Eur J Med Res; 1998 Jul; 3(7):324-30. PubMed ID: 9682028
[TBL] [Abstract][Full Text] [Related]
13. Piperacillin-tazobactam plus amikacin as an initial empirical therapy of febrile neutropenia in paediatric cancer patients.
Hamidah A; Rizal AM; Nordiah AJ; Jamal R
Singapore Med J; 2008 Jan; 49(1):26-30. PubMed ID: 18204765
[TBL] [Abstract][Full Text] [Related]
14. Isepamicin once daily plus ceftriaxone versus amikacin plus ceftriaxone in febrile neutropenic patients.
Herbrecht R; Blaise D; Espinouse D; Leblond V; Sadoun A; Sauvage C; Cordonnier C; Minozzi C
J Chemother; 1995 Jun; 7 Suppl 2():103-10. PubMed ID: 8622099
[TBL] [Abstract][Full Text] [Related]
15. [Management of 315neutropenic febrile episodes in a cancer center].
Dutronc H; Billhot M; Dupon M; Eghbali H; Donamaria C; Dauchy FA; Reiffers J
Med Mal Infect; 2009 Jun; 39(6):388-93. PubMed ID: 19062208
[TBL] [Abstract][Full Text] [Related]
16. Panipenem versus cefepime as empirical monotherapy in adult cancer patients with febrile neutropenia: a prospective randomized trial.
Kwon KT; Cheong HS; Rhee JY; Wi YM; Ryu SY; Heo ST; Moon CS; Ki HK; Kim KH; Jung CW; Peck KR; Song JH
Jpn J Clin Oncol; 2008 Jan; 38(1):49-55. PubMed ID: 18203711
[TBL] [Abstract][Full Text] [Related]
17. [Value of mono-antibiotic therapy using piperacillin associated with sulbactam and possibly followed by vancomycin in febrile neutropenia in solid tumors].
Abs L; Kattan J; Culine S; Bekradda M; Farhat F; Droz JP
Bull Cancer; 1994 Oct; 81(10):871-6. PubMed ID: 7734770
[TBL] [Abstract][Full Text] [Related]
18. High-risk febrile neutropenia in Auckland 2003-2004: the influence of the microbiology laboratory on patient treatment and the use of pathogen-specific therapy.
Ritchie S; Palmer S; Ellis-Pegler R
Intern Med J; 2007 Jan; 37(1):26-31. PubMed ID: 17199841
[TBL] [Abstract][Full Text] [Related]
19. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure.
Miranda-Novales MG; Belmont-Martinez L; Villasis-Keever MA; Penagos-Paniagua M; Bernaldez-Rios R; Solorzano-Santos F
Arch Med Res; 1998; 29(4):331-5. PubMed ID: 9887552
[TBL] [Abstract][Full Text] [Related]
20. Infectious complication in 314 patients after high-dose therapy and autologous hematopoietic stem cell transplantation: risk factors analysis and outcome.
Gil L; Styczynski J; Komarnicki M
Infection; 2007 Dec; 35(6):421-7. PubMed ID: 17926001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
